Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer°Fs disease." Biochemical biomarkers of late-life dementia

Alzheimer's and Dementia

Volumn 2, Issue 4, 2006, Pages 287-293

  Clark, Christopher M ^a   Pratico, Domenico ^a   Shaw, Lesley M ^a   Leight, Susan ^a,b   Xie, Sharon X ^a   Gu, Amy ^a   Lee, Virginia M Y ^a,b   Trojanowski, John Q ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE INHIBITOR; ISOPROSTANE DERIVATIVE; LIPOXYGENASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTICAL ERROR; ARTICLE; COGNITION; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEWY BODY; MEDICAL RESEARCH; METHODOLOGY; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RATING SCALE; SENSITIVITY AND SPECIFICITY;

EID: 33749512773     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.05.2347     Document Type: Note

References (27)

1. Forman M.S., Farmer J., Johnson J.K., Clark C.M., Arnold S.E., Coslett H.B., et al. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol (2006) (In press)
2. Grossman M., Farmer J., Leight S., Work M., Moore P., Van D.V., et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer°Fs disease. Ann Neurol 57 5 (2005) 721-729
3. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., et al. Biological markers for therapeutic trials in Alzheimer°Fs disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer°Fs disease. Neurobiol Aging 24 4 (2003) 521-536
4. Blennow K., Vanmechelen E., and Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer°Fs disease. Mol Neurobiol 24 1-3 (2001) 87-97
5. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 12 (2003) 1696-1702
6. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61 1 (2004) 95-102
7. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer°Fs disease in patients with mild cognitive impairment. Acta Neurol Scand 179 Suppl (2003) 47-51
8. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166 1 (2000) 201-203
9. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 4 (2002) 627-629
10. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer°Fs disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 3 (2006) 228-234
11. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 7 (1998) 937-945
12. Galasko D. Biological markers and the treatment of Alzheimer°Fs disease. J Mol Neurosci 17 2 (2001) 119-125
13. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol 59 3 (2006) 512-519
14. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., et al. MRI and CSF studies in the early diagnosis of Alzheimer°Fs disease. J Intern Med 256 3 (2004) 205-223
15. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., et al. The Role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20 1 (2006) 6-15
16. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 8 (2001) 759-767
17. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 12 (2001) 4183-4187
18. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., Morrow J.D., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128 1-2 (2004) 117-124
19. Montine T.J., Markesbery W.R., Morrow J.D., and Roberts L.J. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer°Fs disease. Ann Neurol 44 3 (1998) 410-413
20. Montine T.J., and Morrow J.D. Fatty acid oxidation in the pathogenesis of Alzheimer°Fs disease. Am J Pathol 166 5 (2005) 1283-1289
21. 2-isoprostanes in Alzheimer°Fs disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12 (1998) 1777-1783
22. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., and Fitzgerald G.A. Increased 8,12-iso-iPF2a-VI in Alzheimer°Fs disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48 5 (2000) 809-812
23. Pratico D., Clark C.M., Liu F., Lee V.Y.-M., and Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment. A possible predictor of Alzheimer disease. Arch Neurol 59 (2002) 972-976
24. Pratico D., and Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer°Fs disease. J Alzheimers Dis 6 2 (2004) 171-175
25. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27 3 (2006) 394-401
26. Montine T.J., Quinn J.F., Milatovic D., Silbert L.C., Dang T., Sanchez S., et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer°Fs disease. Ann Neurol 52 2 (2002) 175-179
27. Pratico D., Zhukareva V., Yao Y., Uryu K., Funk C.D., Lawson J.A., et al. 12/15-lipoxygenase is increased in Alzheimer°Fs disease: possible involvement in brain oxidative stress. Am J Pathol 164 5 (2004) 1655-1662